Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8TET4
UPID:
GANC_HUMAN
Alternative names:
-
Alternative UPACC:
Q8TET4; Q52LQ4; Q8IWZ0; Q8IZM4; Q8IZM5
Background:
Neutral alpha-glucosidase C plays a pivotal role in carbohydrate metabolism by catalyzing the hydrolysis of alpha-glucosidic linkages in oligosaccharides and polysaccharides, converting them into monosaccharides. This enzyme's activity is crucial for the proper digestion of complex carbohydrates and their subsequent absorption and utilization by the body.
Therapeutic significance:
Understanding the role of Neutral alpha-glucosidase C could open doors to potential therapeutic strategies. Its alpha-glucosidase activity suggests a significant impact on metabolic processes, which, if modulated, could lead to novel treatments for metabolic disorders.